By John Casey, Director, Biologics Contract Manufacturing, Jon Best, Director, Business Development
The process of developing and manufacturing a monoclonal antibody (mAb) therapeutic can be overwhelming. With numerous variables impacting product quality, many organizations developing these complex molecules require proven expertise and support to timely deliver a safe, reliable therapeutic that meets patient needs.
By choosing AbbVie, you’re partnering with a highly experienced and trusted organization that has brought many Biologics to market. Much more than a CMO, AbbVie is an established biopharmaceutical partner to provide comprehensive support at every phase of your mAb’s development to commercial life cycle.
With a long-standing track record in biopharmaceutical process development, a knowledgeable scientific team, world-class global facilities, and exceptional end-to-end Biologics capabilities, AbbVie has a comprehensive platform to support the development, manufacture and commercialization of your Biologics therapeutic. Robust quality systems are in place to assure consistent, high quality supply, providing you with confidence in milestone achievement. Moreover, our total commitment to treating your program as if it were our own ensures strong collaboration and ultimate success all the way from innovation to commercialization.